Palliative Care for Multiple Myeloma

Overseen By Renato Samala, MD

Age: 18+

Sex: Any

Trial Phase: Academic

Sponsor: Case Comprehensive Cancer Center

Disqualifiers: Prior palliative care, Hospice transition

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Approved in 4 Jurisdictions This treatment is already approved in other countries

Compensation: Varies

Number of Visits: Unknown

20 Participants Needed

Trial Summary

What is the purpose of this trial?

Multiple Myeloma (MM) is a common type of cancer involving the cells in the blood (commonly affecting bones, kidneys and blood). Although it remains incurable, MM has become a highly treatable form cancer thanks to new and improved treatment modalities. As patients deal with this disease, they often suffer from multiple symptoms that are caused by both the disease itself and the different drugs used to treat it. Research has shown that the most common symptoms patients suffer from include pain, constipation, tiredness, tingling in hands and feet, breathlessness, sadness and difficulty remembering things. These symptoms may negatively affect the quality of life of patients. Palliative care (PC) is a type of treatment aimed at relieving symptoms and promoting the most optimal quality of life (QOL) for patients and their caregivers. Research has shown that patients with certain types of cancers, such as colon cancer and lung cancer, do better if they are seen by a PC provider early in the course of their disease. This study seeks to determine the effects of early PC involvement on participants with newly diagnosed MM

Research Team

Renato Samala, MD

Principal Investigator

The Cleveland Clinic

Eligibility Criteria

This trial is for English-speaking individuals recently diagnosed with symptomatic Multiple Myeloma, within eight weeks. They should be able to perform daily activities with varying degrees of assistance (ECOG status 0-3) and must be receiving care at a Cleveland Clinic facility. Those who have already seen a Palliative Care provider or require immediate hospice care cannot participate.

Inclusion Criteria

Able to read and respond to questions in English

You are currently getting cancer treatment at a Cleveland Clinic facility.

I can care for myself but may not be able to do heavy physical work.

Exclusion Criteria

Have seen a PC provider in any setting (i.e., inpatient, outpatient or home-based)

I need to be referred to palliative care for end-of-life care.

Treatment Details

Interventions

• Palliative Care

Trial Overview The study is examining the impact of early Palliative Care on quality of life for new Multiple Myeloma patients. It involves assessing symptom relief and well-being using specific questionnaires like FACT-MM and HADS during the treatment process.

Participant Groups

Group I: Early Palliative Care Integration Experimental Treatment 3 Interventions

12 months of PC with concurrent standard treatment for MM, QOL assessments

Palliative Care is already approved in European Union, United States, Canada for the following indications:

Approved in European Union as Palliative Care for:

• Symptom management for various conditions including cancer, neurological disorders, and end-of-life care

Approved in United States as Palliative Care for:

• Symptom management for various conditions including cancer, neurological disorders, and end-of-life care

Approved in Canada as Palliative Care for:

• Symptom management for various conditions including cancer, neurological disorders, and end-of-life care

Who Is Running the Clinical Trial?

Case Comprehensive Cancer Center

Lead Sponsor

Trials

472

Recruited

33,400+